GET DAILY SIGNALSIovance Biotherapeutics (IOVA) Stock Drops -47% After Lung Cancer Trial Update
Key Takeaways
- Iovance Biotherapeutics shares fell roughly 47% over the trailing 30 days, declining from about $14.21 to near $7.54 as of November 13, 2026.
- The sharpest single-day move came on October 29, 2026, when the stock dropped about 35% following updated Phase 2 IOV-LUN-202 lung cancer data for lifileucel.
- The overall objective response rate held near prior results, but an 11.4% response in the KRAS-mutant subgroup raised doubts about the broader lung cancer opportunity.
- Management pivoted to a "precision TIL" strategy, announcing the POSITILITY trial and a planned 2027 frontline OPTILISM study.
- The decline reversed much of a powerful 2026 rally; the stock remains far below its late-October peak near $15 despite holding above its 52-week low.
- Commercial fundamentals stayed intact, with second-quarter 2026 product revenue up 66% year over year and raised full-year guidance.
- For deeper data, review Iovance's Price Targets, Earnings, and Forecast pages.
Company Background: Iovance Biotherapeutics (IOVA)
IOVA is a commercial-stage biotechnology company and the global leader in tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its flagship product, Amtagvi (lifileucel), is the first FDA-approved, one-time TIL therapy for previously treated advanced melanoma and is now approved in three global markets, available at nearly 100 authorized treatment centers.
The company operates an end-to-end cell therapy business built around fully owned, centralized U.S.-based manufacturing. Beyond melanoma, IOVA is advancing lifileucel across registrational trials in non-small cell lung cancer (NSCLC), soft tissue sarcoma, and endometrial cancer, alongside next-generation programs including gene-edited and IL-12 tethered TIL therapies. Investors follow the stock closely because Amtagvi's commercial ramp and the potential expansion into the much larger lung cancer market represent the company's two central value drivers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: The -47% Slide Over 30 Days
Over the last 30 days, IOVA shares have fallen approximately 47%, dropping from a closing price near $14.21 in mid-October to about $7.54 as of November 13, 2026. The overwhelming majority of that decline occurred in a single session, when the stock fell roughly 35% on October 29 after the company released updated lung cancer trial data.
The quarterly picture is more complex. Beginning the three-month period near $6.50 in mid-August, the stock surged through September and October, reaching a 52-week intraday high near $15.37 in late October. The subsequent data-driven selloff erased most of those gains, leaving the shares up roughly 16% for the quarter overall — but down more than 50% from their recent peak. In short, the quarter was defined by a sharp rally followed by an equally sharp repricing.
What Drove the October 29 Selloff
The defining catalyst was the October 29, 2026 update from the Phase 2 IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic NSCLC. Iovance reported an overall objective response rate of 24.6% across 69 patients, essentially in line with the 25.6% previously shown in 39 patients. However, the responses were heavily concentrated in a biomarker-enriched subgroup: patients without KRAS mutations showed a 43.3% response rate, reaching 59.1% when HER2 wild-type status and smoking history were added. By contrast, the KRAS-mutant subgroup — a larger portion of the cohort — responded at only 11.4%, below the roughly 12.8% rate associated with standard-of-care treatment for that population.
The market's reaction reflected a shift in how the lung cancer opportunity is valued. Investors had priced in a broader registrational pathway, and the subgroup-dependent results prompted a reassessment. The selloff was compounded by analyst actions: Baird lowered its price target to $9 from $11, while the broader biotech tape remained under pressure from rising long-term Treasury yields. Notably, Goldman Sachs had resumed coverage with a Buy rating and a $15 target ahead of the move, underscoring how divided sentiment became around the data.
Quarterly Trends and Commercial Momentum
The quarterly trend was shaped by strong commercial execution colliding with clinical uncertainty. IOVA's stock rallied sharply in August after second-quarter results showed total product revenue of about $99.3 million, up 66% year over year and ahead of guidance, and the company subsequently raised its full-year 2026 revenue outlook to between $410 million and $420 million. The growing authorized treatment center network and a cash runway extending into the second half of 2028 reinforced the bullish case.
That momentum carried the stock to its 52-week high near $15.37 by late October, fueled by anticipation of the lung cancer data and positive ESMO 2026 presentations. The October 29 data release then triggered a rapid repricing, as investors recalibrated expectations for a broad lung cancer label in favor of a more narrowly defined, biomarker-selected population. The net result was a quarter of exceptional volatility that ended with only modest gains intact.
Key Factors to Watch Going Forward
Looking ahead, the most important factors for IOVA will be the execution of its precision medicine strategy in lung cancer. Investors will monitor enrollment in the POSITILITY trial, which began in November 2026, as well as progress toward the planned OPTILISM frontline study in 2027 and any FDA feedback on the registrational pathway. Continued growth in Amtagvi sales for melanoma, treatment center expansion, and progress toward additional approvals — including a potential U.K. decision — will also shape sentiment.
Macroeconomic conditions remain relevant, as rising long-term interest rates can pressure valuations of pre-profit biotech companies. Finally, updated analyst price targets and the pace of cash consumption will be closely watched, given that the company expects its current resources to fund operations into the second half of 2028. These factors carry meaningful uncertainty, and outcomes may differ materially from current expectations.
My Take on Tickeron’s AI Trading Bots
In my own research process, I frequently review Tickeron’s AI Trading Bots to observe how automated strategies are handling volatile names like this one. The platform offers hundreds of bots across thousands of tickers, with top performers highlighted in real time. It gives me a quick way to compare short-term momentum approaches against longer-horizon trend models without building everything from scratch. This has helped me stay objective when clinical data shifts the narrative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
IOVA's Stochastic Oscillator sits in oversold zone for 9 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 201 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IOVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 145 of 164 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
IOVA moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IOVA crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.038) is normal, around the industry mean (3.498). P/E Ratio (-11.652) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biotechnological products for the treatment of cancer
Industry Biotechnology
Advertisement